We're proud to receive a 2025 CDMO Leadership Award in the “Small Molecule Dosage Form - Global" category.
For companies pursuing an orphan drug, successfully traversing the path to regulatory submission requires striking the right balance of speed-to-clinic and cost. While there is no one-size-fits-all approach, shared characteristics of successful development projects include:
In this whitepaper, our experts help guide you through the complex challenges of getting your small molecule orphan drug to market faster.